ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Volastra Therapeutics will receive $30 million from Bristol Myers Squibb as part of an agreement to discover synthetic lethal targets as drug candidates. Synthetic lethality is a method of exploiting vulnerabilities in tumor cells to induce tumor death while sparing normal cells. Volastra’s CINtech platform is intended specifically to exploit chromosomal instability in tumor cells. The firm was founded in 2020 by renowned cancer researcher Lewis Cantley and others.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X